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Objectives: The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in
plasma and CSF was compared in patients with neurological disorders in a multicentre study.
Methods: Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads
were .50 copies/mL in both compartments and bulk genotypic tests were realized.
Results: On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive
patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in
2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%)
patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two
mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P¼0.0455) and T215Y
(P¼0.0455).
Conclusions: In most cases, resistance mutations were present and similar in both studied compartments.
However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF
than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is
performed.
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Introduction
Infection of the CNS with HIV can lead to the development of
HIV-1-associated dementia, HIV-1 encephalitis or neurological
disorders. Although treatment with fully active antiretrovirals
(ARVs) has reduced the frequency of HIV-1 infection of the CNS,
neurological disorder symptoms are still observed in HIV-1
ARV-naive and ARV-treated patients.1 – 6
It is known that HAART has an effect on HIV-1 RNA levels in
CSF.7 Due to the blood–brain barrier, ARV may not be at optimal
therapeutic concentrations in the CNS compartment. Low thera-
peutic concentrations of the ARV could contribute to viral resist-
ance, and consequently, lead to virological failure.8 Such
differences in ARV concentrations in several compartments
could result in discordant HIV-1 RNA levels between plasma and
CSF and/or ARV drug resistance mutations.9 – 12 Differences in ARV
drug resistance mutations between plasma and CNS compart-
ments have been reported as case reports or in small cohorts of
patients.9 – 12
Currently, little information on the resistance patterns in the
CNS is actually available in clinical practice in a large cohort of
patients having a viral load (VL) .50 copies/mL in plasma and
in CSF. In this study, the resistance of HIV-1 in plasma and CSF
was studied and compared in a multicentre study supported by
the ‘Agence Nationale de Recherche sur le Sida et les He´patites
Virales’ (ANRS).
Methods
Patients
We studied all CSF–plasma pairs with detectable VL (.50 copies/mL)
between 2000 and 2013 in 22 centres in France and one centre in
Switzerland. The indications for lumbar puncture are reserved for people
affected by severe cognitive impairment without aetiological orientation.
Socio-demographic and clinical data as well as treatment regimen were
collected for all studied patients. Participating laboratories belong to
ANRS and participate in the ANRS quality control assessment of HIV-1
drug resistance sequencing.13 The study was approved by the scientific
committee of Action Coordonne´e 11-AC11 ANRS.
Genotyping resistance testing
The reverse transcriptase (RT) and protease resistance mutations were
determined in each laboratory using the ANRS consensus technique
(http://www.hivfrenchresistance.org), a Bayer TrueGene Kit, an Abbott
ViroSeq Kit or an in-house method. In ARV-naive patients, protease and
RT mutations were identified from the consensus statement of the list
for genotypic surveillance of transmitted HIV-1 drug resistance.14 In
ARV-treated patients, RT and protease mutations were identified from
the last International AIDS Society-USA resistance testing panel (http://
www.iasusa.org) and were interpreted with the last ANRS genotypic
algorithm (version 23; http://www.hivfrenchresistance.org). According to
the ANRS algorithm, the global genotypic susceptibility score (GSS) was
calculated on ARV currently available (n¼18) as follows: 1 for a sensitive
drug and 0 for a resistant or possible resistant drug. The GSS was also
calculated according to Standford and Rega algorithms.
Statistical methods
Quantitative variables were summarized by means of median and IQR and
qualitative variables by percent. Comparisons between independent
groups were performed using the Kruskal–Wallis non-parametric test.
The McNemar test was applied to compare the prevalence of mutations
in both plasma and CSF in the same group of patients. No correction for
multiple testing was made and the analysis was done with SAS (ver-
sion 9.4).
Results
In total, 244 patients who experienced VL .50 copies/mL in
plasma and CSF at the time of neurological disorders were
Table 1. Characteristics of the studied population (n¼244)
Characteristic ARV-naive patients (n¼89) ARV-treated patients (n¼155)
Age (years), median (IQR) 42 (37–50) 44 (38–51)
Male, % 68.8 61.0
B subtype in CSF, % 55.8 51.0
B subtype in plasma, % 54.8 51.1
CSF HIV-1 RNA (log10 copies/mL), median (IQR) 4.64 (3.78–5.23) 4.09 (3.45–4.71)
Plasma HIV-1 RNA (log10 copies/mL), median (IQR) 5.10 (4.54–5.72) 3.70 (2.73–4.69)
Nadir CD4 (cell count/mm3), median (IQR) 119 (27–332) 59 (18–156)
CD4 (cell count/mm3), median (IQR) 131 (38–343) 230 (102–413)
Current treatment, %
NRTIs+PIs NA 62.6
NRTIs+PIs+INIs+other NA 11.0
NRTIs+NNRTIs NA 5.2
PIs NA 5.2
other NA 16.0
NA, not applicable; INIs, integrase inhibitors.
The other combinations were present at ,5%: NRTIs; NRTIs+PIs+entry inhibitors; PIs+entry inhibitors; NRTIs+PIs+INIs; NRTIs+PIs+INIs+entry
inhibitors; NRTIs+NNRTIs+PIs+entry inhibitors; NRTIs+INIs; NRTIs+INIs+other; PIs+INIs; NNRTIs+PIs; NRTIs+NNRTIs+PIs; NRTIs+NNRTIs+
PIs+INIs+other.
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recruited; 89 and 155 were ARV naive and ARV treated, respect-
ively. The main characteristics of the study population are
shown in Table 1. In the regimen of ARV-treated patients, the
most frequent NRTIs prescribed were emtricitabine/lamivudine
(47.5%), abacavir (25.8%) and tenofovir (25.0%), and the most
frequent PIs were lopinavir (20.5%), darunavir (14.7%) and ataza-
navir (13.1%). Etravirine was the NNRTI most frequently pre-
scribed (13.1%). Overall, non-B subtypes were present in 47.0%
of cases with a majority of CRF02_AG (20.6%).
In ARV-naive patients, 17.9% (16/89) of patients had at least
one HIV-1 resistance mutation in plasma and 17.9% (16/89) in
CSF. Mutations were associated with resistance in 11.2% (10/89)
and 12.4% (11/89) of patients in plasma and CSF, respectively.
The concordance between CSF and plasma sequences was evi-
denced in 85/89 (95.5%) and 88/89 (98.9%) patients for the
studied positions in RT and protease gene, respectively. The
detection of mutations in CSF and not in plasma viruses was
reported in 2/89 (2.2%) patients for the RT gene and in 1/89
(1.1%) patients for the protease gene (Table 2). Some mutations
were also present in plasma and not in CSF in 2/89 (2.2%)
patients for the RT gene (Table 2). Furthermore, 96.6% (86/89)
of ARV-naive patients had viruses with a similar global GSS
in the two compartments, 3.4% (3/89) with a global GSS in
CSF , GSS in plasma, and none with a global GSS in CSF . GSS
in plasma (Figure 1).
In ARV-treated patients, the RT and protease amplification
was successful for 152 and 151 cases, respectively, resulting in
complete paired sequences for 148 patients. Mutations induced
HIV-1 resistance at least for one drug for 111/148 (75.0%)
patients and 110/148 (74.3%) in CSF and plasma, respectively.
Nineteen of 152 (12.5%) patients had HIV-1 mutations only pre-
sent in the CSF for the RT gene and 30/151 (19.8%) patients for
the protease gene (Table 3). Two mutations were statistically
more prevalent in the CSF in comparison with the plasma for
the RT gene: M41L (P¼0.0455) and T215Y (P¼0.0455). There
was no statistically significant difference for the presence of pro-
tease gene mutations. Some patients also presented HIV-1 muta-
tions in plasma and not in CSF: 16/152 (10.5%) and 21/151
(13.9%) for RT and protease gene, respectively (Table 2). One
mutation for the RT gene was statistically significantly more
prevalent in plasma than in CSF: T69N (P¼0.0455). Furthermore,
79.7% (118/148) of ARV-treated patients had viruses with a simi-
lar global GSS of current treatment in the two compartments
whatever algorithm was used, 11.5% (17/148) with a global GSS
in CSF , GSS in plasma and 8.8% (13/148) with a global GSS in
CSF. GSS in plasma (Figure 1). No correlation of CNS-penetration
effectiveness (CPE) score and any studied parameters was
evidenced.
Discussion
In this multicentre study, the ARV resistance in 244 HIV-1 patients
with neurological disorders and HIV-1 RNA load.50 copies/mL in
plasma and CSF was studied in both compartments. In most
cases, HIV-1 resistance was similar in plasma and CSF. However,
we identified some cases where HIV-1 was more resistant in CSF
than in plasma, reducing the number of future therapeutic
options, in the studied population.
In ARV-naive patients, the prevalence of transmitted drug
resistance was 11.2% in plasma. Similar results (9.0%) were
described in the national sentinel surveillance of transmitted
drug resistance in ARV-naive chronically HIV-1-infected patients
in France over a decade (2001–11).15 The prevalence of HIV-1
drug resistance in ARV-treated patients in this study was superior
to that previously shown in 2009 in a French nationwide study
(59%), possibly because the present study population was more
advanced with higher VL (3.70 versus 2.57 log10 copies/mL) and
lower CD4 (230 versus 390 cells/mm3).16
Overall, a good concordance of resistance pattern was
observed in CSF and plasma, but some resistance mutations can
Table 2. Differential pattern of resistance in ARV-naive and ARV-treated patients
ARV-naive
patients, RT
ARV-naive patients,
protease ARV-treated patients, RT ARV-treated patients, protease
CSF
detection of mutations 2.2% (2/89) patients 12.4% (11/89) patients 12.5% (19/152) patients 19.8% (30/151) patients
mutations K101E, Y181C,
M184I, T215Y
L10I/V, V11I, L33F/V,
M36I, I62V, L63P,
V77I, V82A, L89M
M41L, K65R, D67N, T69D, K70R,
L74V, K101E, K103N, V108I,
F116Y, Q151M, Y181C, M184V,
M184I, G190A, L210W, T215Y,
T215F, H221Y, M230I
L10I, L10F, V11I, K20R, K20I, K20T,
M36I, M36L, M46I, F53L, I62V,
L63P, I64L, I64V, A71V, A71I,
A71L, V77I, V82 T, V82A, L89V,
L89M, L90M, I93L, I93M
Plasma
detection of mutations 2.2% (2/89) patients 9.0% (8/89) patients 10.5% (16/152) patients 13.9% (21/151) patients
mutations Y181I, M184I L10I, V11I, G16E, M36I,
I62V, L63P, I64V,
V77I, I93L
D67N, T69N, K70R, K70E, L74V,
V90I, V106I, V106M, V108I,
E138Q, Y181C, Y188L, M184I,
M184V, L210W, K219E, M230L
L10I, L10F, G16E, K20I, L24I, V32I,
L33I, L33F, M36I, M36L, M46I,
I47V, G48V, I50L, I54V, I54L,
I54M, Q58E, D60E, I62V, L63P,
I64V, I64M, H69K, A71V, A71T,
L76V, V77I, V82A, V82I, V82T,
I85V, L89M, L90M, I93L
In bold, mutations appeared statistically more prevalent: in CSF, M41L (P¼0.0455) and T215Y (P¼0.0455); and in plasma, T69N (P¼0.0455).
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be detected only in CSF or in plasma. In addition, some attention
should also be paid to patients with similar global GSS in both
compartments, because the resistance mutation set could be dif-
ferent, resulting in different ARV resistance. Our results were simi-
lar to a systematic review pooling 35 reports with heterogeneous
design and methods.17 Several factors could explain the discord-
ant presence of HIV-1 mutations and/or ARV resistance between
the plasma and the CSF, such as insufficient drug exposure,9 pre-
vious discontinuation of treatment,18 independent replication and
evolution of resistance in the CNS,19 CNS infection leading to local
immune activation20,21 or previous virological failure in plasma
allowing archiving of ARV-resistant HIV-1 strains in the CNS com-
partment.10 The CNS drug penetration appeared to be an import-
ant factor in the pathogenesis of CSF viral escape.22 The CPE score
was developed by Letendre23 to calculate a CPE score adjusted
for each regimen. In case of neurological disorders, the ARTshould
be based not only on drug penetration but also on HIV-1 resist-
ance in CSF. It should be mentioned that these cases of discord-
ance between blood and CSF remain relatively uncommon.
Furthermore, analysis of plasma and CNS samples also by Ultra
Deep P Sequencing can provide a deeper characterization of
drug resistance mutations and HIV-1 quasi-species in both com-
partments. This new-generation sequencing could highlight either
some additional discordances or concordances with different per-
centages in both compartments.
It is noteworthy that the two mutations statistically signifi-
cantly more prevalent in CSF than in plasma were M41L and
T215Y. This may be related to thymidine analogues that have a
good penetration into the CNS compartment, allowing appear-
ance of the virus mutation, probably due to drug pressure.8
More attention has to be paid to pharmacological CNS drug pene-
tration not only to treat neurological disorders but also to prevent
ARV resistance, despite the difficulties of evaluati individual CNS
drug concentration.
In conclusion, these results from a large cohort from clinical
routine care evidenced discordance in HIV-1 mutations and/or
resistance between the plasma and the CSF in HIV-1 patients
with neurocognitive symptoms. Furthermore, in 3.4% of ARV-
naive and 8.8% of ARV-treated patients, the virus was more resist-
ant in CSF than in plasma. These results support the need to
perform genotypic resistance testing when VL is .50 copies/mL
in CSF.
GSS in plasma
GSS in CSF 
9 10 11 12 14 15 16 17 18 Patients (n)
9 1 1
11 1 1
12 1 1
14 1 2 3
15 3 3
16 2 2
17 1 1
18 2 75 77
Patients (n) 1 1 1 1 2 3 2 3 75 89
GSS in
plasma 
GSS in CSF
2 3 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Patients 
(n)
2 1 1
3 1 1
4 1 1
5 2 2
6 2 1* 3
7 2 2
8 2 2
9 1 1
10 1 1 1 3
11 4 4
12 1 4 1 1 1 8
13 1 7 8
14 1 1 1 14 1 18
15 9 1 1 11
16 1 1 13 1 1 17
17 1 2 23 2 28
18 1 5 32 38
Patients (n) 1 1 4 3 2 2 3 2 5 5 10 17 12 14 30 37 148
(a)
(b)
Figure 1. Comparison of global GSS of HIV-1 viruses in plasma and CSF compartments in (a) ARV-naive patients and (b) ARV-treated patients. The results
are expressed in the table as the number of patients having a global GSS in plasma and in CSF. *This patient had a global GSS at 11 in CSF and 6 in plasma.
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Table 3. Description of treated patients with discordant mutations between the CSF and plasma HIV-1 sequences
Patient Treatment CPE Subtype
CSF Plasma
VL (log10 copies/mL) RT protease VL (log10 copies/mL) RT protease
1 f3TC, ddI, NVP 8.5 CRF01_AE 4.31112 V108I 4.15921
2 f3TC, TDF, ETR 5.5 B 4.30103 K20R, L63P 5.63347 E138Q
3 f3TC, TDF, ETR 5.5 D 4.54845 M41L, L210W, T215Y V82T M230L L33I, I50L, I64V
4 f3TC, ABC,
TDF, NVP
10.5 B 3.61805 Y181C, M184V,
T215Y, H221Y
5.71850
5 f3TC, ABC, DRV 8.5 C 4.93952 K20R 3.55630 Y188L V82I
6 f3TC, ABC, fAPV 8.5 3.64345 L10F, L10I 2.32428 M36I
7 f3TC, TDF, fAPV 6.5 B 5.45618 M41L, L74V, Y181C,
M184V, L210W,
T215Y, K103N
2.90741
8 f3TC, TDF, ATV 5.5 B 4.64640 K103N 4.22272 T69N
9 AZT, SQV, LPV 8 CRF02_AG 4.96480 L90M 3.75664
10 AZT, f3TC, SQV 7.5 B 3.89209 3.98677 Q58E, I62V, V82I,
I85V, L90M
11 f3TC, TDF, ATV 5.5 B 3.31492 A71V, L90M 5.13374 Q58E, A71T
12 f3TC, TDF, LPV 6.5 CRF02_AG 3.44592 M184V 2.21484 V90I
13 AZT, ABC, LPV 10 CRF06_CPX 5.14993 M46I 2.07555
14 f3TC, d4T, ddI,
ABC, SQV,
NFV, LPV
14.5 B 3.21958 4.53842 D67N, K70R, Y181C,
L210W, K219E
M46I, L63P, A71V, V77I
15 f3TC, ABC, LPV 8.5 CRF02_AG 3.41497 4.59356 M184I, M184V K20I, M36I, H69K, L89M
16 f3TC, TDF, LPV 6.5 B 3.20683 M36I 6.78056 I93L
17 ddI, TDF, ATV 5 B 3.68422 A71L, A71V 2.27416 A71T
18 f3TC, ABC, ATV 7.5 B 3.29667 M46I, I93M 3.58894
19 f3TC, ddI, ATV 6.5 B 4.02612 V77I 3.20466 A71T
20 ddC, TDF, fAPV 5 C 3.27875 L89M 3.64345 M46I, I47V, I54M
21 f3TC, TDF, ATV 5.5 B 3.00346 Q151M 2.81158 V90I
22 f3TC, TDF, LPV 6.5 A 5.23553 M184I 5.53921
23 f3TC, TDF, DRV 6.5 B 2.14613 T69D F53L, V82A 5.41497 T69N L10F, V82T
24 AZT, f3TC, ATV 8.5 B 4.76641 M36I, V77I 3.75694
25 f3TC, ABC, IDV 9.5 B 4.77815 M46I 2.45637
26 ABC, TDF, DRV 7 ind 4.63347 3.43136 L74V, V106I, V106M
27 f3TC, ddI, SQV 5.5 CRF02_AG 4.36736 D67N 4.51720 M184I
28 AZT, f3TC, LPV 9.5 CRF02_AG 3.64738 I64L 5.41159 L63P
29 f3TC, ddI, NFV 5.5 CRF09_cpx I62V 2.54283
30 f3TC, ABC, IDV 9.5 B 3.61278 M41L, L74V 3.88480
31 f3TC, ETR, DRV, RAL 10.5 B 4.56820 H221Y 4.60206
32 AZT, f3TC, IDV, T20 11.5 B 3.96848 M36L 2.62325 T69N M36I
33 AZT, f3TC, NVP, LPV 13.5 B 2.40140 M230I M36I 2.37107
34 ETR, DRV, RAL 8 B M36I, I64V, I93L 3.69992 L10I, L24I, L33F, M36L,
M46I, I50L, Q58E, I62V,
I64M, V82A, L89M
35 f3TC, ABC, DRV 11.5 B 3.87679 K20I, A71L, A71V 2.80140 D67N, T69N, K70R,
Y181C, K219E
36 AZT, f3TC, ABC, TDF 10.5 B 4.57287 2.36361 V82A
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